T. Rowe Price Investment Management, Inc. Celldex Therapeutics, Inc. Transaction History
T. Rowe Price Investment Management, Inc.
- $162 Billion
- Q4 2024
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 1,697,498 shares of CLDX stock, worth $36.3 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
1,697,498
Previous 1,734,522
2.13%
Holding current value
$36.3 Million
Previous $59 Million
27.24%
% of portfolio
0.03%
Previous 0.04%
Shares
2 transactions
Others Institutions Holding CLDX
# of Institutions
199Shares Held
60.6MCall Options Held
960KPut Options Held
675K-
Kynam Capital Management, LP Princeton, NJ5.06MShares$108 Million8.11% of portfolio
-
Black Rock Inc. New York, NY4.69MShares$100 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.88MShares$82.9 Million0.0% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.75MShares$80.2 Million1.82% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.56MShares$76 Million0.01% of portfolio
About Celldex Therapeutics, Inc.
- Ticker CLDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,772,400
- Market Cap $999M
- Description
- Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...